Published: 28 March 2022
Author(s): M Carrier, TF Wang
Issue: June 2022
Section: Commentary

Venous thromboembolism (VTE) is a common complication among patients with cancer. The 6-month risk of VTE complication for cancer patients is 12-fold higher and as much as 23-fold higher in those receiving chemotherapy or targeted therapy when compared to patients without cancer [1]. Furthermore, the 12-month cumulative incidence for VTE has increased three-fold over the past two decades in this patient population [1]. Hence, cancer-associated thrombosis (CAT) is a frequent complication that most clinicians caring for patients with cancer must routinely manage.

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.